Status:
UNKNOWN
Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.
Lead Sponsor:
Instituto Nacional de Cancerologia de Mexico
Conditions:
Non-Hodgkin Lymphoma
Eligibility:
All Genders
15-60 years
Brief Summary
The purpose of this study is to determine whether a specific subtype of lymphoma responds optimally to treatment with rituximab and chemotherapy.
Detailed Description
Treatment with rituximab and chemotherapy (R-CHOP)is the accepted treatment for young patients with diffuse large B cell Non-Hodgkin's Lymphoma. However not every patient benefits with this expensive ...
Eligibility Criteria
Inclusion
- Diagnosis of Large B cell Non-Hodgkin Lymphoma CD20+
- BCL-6 negative
- Age \< 61 years old
- ECOG 2 or less
- IPI low, low intermediate
- Stage II, III or IV
- Signed Informed Consent
Exclusion
- Stage I
- Previous treatment
- Lymphomatous central nervous system involvement
- Heart disease
- Kidney failure (serum creatinine \> 2 mg/dl)
- HIV +
- Viral Hepatitis
- Pregnancy
Key Trial Info
Start Date :
January 1 2007
Trial Type :
OBSERVATIONAL
End Date :
January 1 2007
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00429065
Start Date
January 1 2007
End Date
January 1 2007
Last Update
January 31 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto Nacional de Cancerologia
Mexico City, D.F., Mexico, 14080